NASDAQ · STAA
STAAR Surgical Company
Healthcare · Medical - Instruments & Supplies
$25.32▲ 3.17% ($0.78)today
As of 12:43 PM ET
Valuation
Revenue & margin DCF
A cash-flow estimate wouldn't be reliable here
More than 85% of this valuation sits in the terminal value beyond year 10, so the result is driven by the perpetuity assumption rather than the projected decade. The valuation is not shown.
- 10-yr revenue CAGR
- 19.0%
- Ending operating margin
- 10.3%
- Discount rate
- 9.9%
USD · TTM ending Jul 3, 2026 · Price used $25.32 · Price Nov 2, 5:43 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock rose 0.3% over the last year. Revenue grew 51.3% over the trailing twelve months. Operating margin moved from -48.83% to 10.32%. Free cash flow grew 84.57% over the trailing twelve months.
What the market seems to be pricing
The stock has moved higher against modestly improving underlying metrics. The operating data does not yet tell a clear story — the move may reflect sentiment, sector rotation, or macro factors rather than company-specific earnings power.
What would invalidate this read
Operating margin currently stands at 10.32%. A decisive move in revenue — currently up 51.3% — would be the clearest signal to resolve the ambiguity.
Return analysis
Company profile
STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation.
Market multiples
Stock splits
Every 2 shares became 1
Every 2 shares became 1
Every 1 shares became 2
Every 1 shares became 2
Profitability & growth
Analyst consensus
5
Buy
9
Hold
2
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Nov 4, 2026
Q3 FY26 · EPS est $0.05 · Revenue est $78.7M
Same quarter, year over year
FY26 YTD n/mEach cell vs the same quarter a year earlier (the cell below) · Q1–Q2 combined $0.54 vs -$0.86 · all 2 quarters up
Q1
Q2
Q3
Q4
FY total
FY26
—
—
FY25
FY24
FY23
—
—
—
Fiscal year totals
- FY25
- -$0.60
- -330.6%
- FY24
- $0.26
- —
n/m: last year’s figure was zero, a loss or too small to compare against
Q2 FY26
Reported Aug 12, 2026 · Latest
HoverTap a cell to inspect
Actual
$0.16
Estimate
$0.22
Year over year
n/m
Vs prior quarter
-57.9%
Institutional Sentiment
STAAR Surgical Company · STAA
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.